ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/26/19

Alexion: Investment Thesis Indicative future rates of return from an investment in Alexion ( ALXN ) shares at the current share price level are in the region of 8% to 9% per year, based on analysts' consensus estimates, and provided the P/E multiple remains around current level. But there ...

Merger activity increased, with nine new deals announced and six deals closing. Deal Statistics New Deals The acquisition of LogMeIn (LOGM) by Francisco Partners for $4.3 billion or $86.05 per share in cash. We added LOGM as a potential deal to the Deals in the Works section on Dece...

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have appr...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and pancreas. All of the company's approved drugs treat CF's underlying causes, and its do...

Amgen (NASDAQ: AMGN ) resumed with Overweight rating and $280 (15% upside) price target at Morgan Stanley. More news on: Amgen Inc., Hill-Rom Holdings, Inc., Johnson & Johnson, Healthcare stocks news, Stocks on the move, , Read more ...

– Option Exercise Triggers $20 Million Payment to Dicerna – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for exclusive rights to two additional targets within th...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Have you Noticed All the Merger Announcements? I Have A feature of this stock market has been accelerated merger announcements. I don’t believe we are at historic levels but I see it accelerating recently. I have said this many times recently, the fact that M&A is going on mea...

Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...